Champions Oncology (CSBR) Stock: Buy, Sell, or Hold?
CSBR - Champions Oncology, Inc.
$5.10
0.00 (0.09%)
â˛
5d:
-3.41%
30d:
+3.03%
90d:
-20.56%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Sep 21, 2026
7d
Get Alerted When CSBR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CSBR is fairly priced but lacks strong directional signals. At -3.4% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CSBR is fairly priced but lacks strong directional signals. At -3.4% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CSBR is currently trading at $5.10, which is considered fair relative to its 30-day fair value range of $4.96 to $5.17. The stock's valuation (Forward PE: 51.0) is in line with its historical norms (56.5). Remarkably, the market is currently pricing in an annual earnings decline of 3.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CSBR is in a strong downtrend. Immediate support is located at $4.85, while resistance sits at $5.51.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.00 (+135.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CSBR is in a strong downtrend. Immediate support is located at $4.85, while resistance sits at $5.51.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.00 (+135.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.96 -
$5.17
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 135.3% below Wall St target ($12.00)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.96 -
$5.17
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.85
Resistance Level
$5.51
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
51.00
Wall Street Target
$12.00
(+135.3%)
Revenue Growth (YoY)
12.0%
Earnings Growth (YoY)
-61.1%
Profit Margin
-2.0%
Valuation Discount vs History
-3.4% cheaper
PE vs Historical
51.0 vs 56.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.4%
(market-implied from PE analysis)
1-Year Target
$4.93
(-3%)
2-Year Target
$4.76
(-7%)
3-Year Target
$4.60
(-10%)
3-Yr Target (if PE normalizes)
(PE: 51â57)
$5.09
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 51.0, Growth: -16.7%)
$3.72
(+-27%)
Base:
(SPY PE: 20.2, Growth: -16.7%)
$1.47
(-71%)
Bear:
(PE: 17.1, Growth: -16.7%)
$1.25
(-76%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 51.0 to 56.5
Stabilization Target:
$5.65
(+10.8%)
PE Expansion Potential:
+10.8%
Share & Embed Analysis
Last updated: September 13, 2026 9:46 AM ET
Data refreshes hourly during market hours. Next update: 10:46 AM
Data refreshes hourly during market hours. Next update: 10:46 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSBR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 44 HOLD |
